Irritable bowel syndrome: an update on treatment options.
Blackington
E
E
Massachusetts General Hospital Institute for Health Professions, Boston, USA.
D000223:Adaptation, Psychological; D000928:Antidepressive Agents / Q000627:therapeutic use; D000930:Antidiarrheals / Q000627:therapeutic use; D002243:Carbolines / Q000627:therapeutic use; D003109:Colonic Diseases, Functional / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000523:psychology / Q000628:therapy*; D003937:Diagnosis, Differential; D004043:Dietary Fiber / Q000008:administration & dosage; D018492:Dopamine Antagonists / Q000627:therapeutic use; D006801:Humans; D008403:Mass Screening / Q000379:methods; D008787:Metoclopramide / Q000627:therapeutic use; D009722:Nurse Practitioners; D010276:Parasympatholytics / Q000627:therapeutic use; D010353:Patient Education as Topic / Q000379:methods; D011320:Primary Health Care / Q000379:methods; D012017:Referral and Consultation; D012307:Risk Factors; D012702:Serotonin Antagonists / Q000627:therapeutic use
D000928:Antidepressive Agents; D000930:Antidiarrheals; D002243:Carbolines; D004043:Dietary Fiber; D018492:Dopamine Antagonists; D010276:Parasympatholytics; D012702:Serotonin Antagonists; C090840:alosetron; D008787:Metoclopramide